Hyperparathyroidism
Hyperparathyroidism occurs when the parathyroid glands, four small glands behind the thyroid, overproduce parathyroid hormone (PTH). Excess PTH pulls calcium from bones into the bloodstream, which over time raises the risk of osteoporosis, kidney stones, and fatigue. The primary form arises from a gland abnormality; secondary hyperparathyroidism develops as a response to low calcium, most often caused by chronic kidney disease or vitamin D deficiency.
Key points
- When kidney disease drives the secondary form, a vitamin D analogue can correct poor calcium uptake and curb excess hormone output.
- Removing the affected gland surgically is considered the definitive treatment when primary disease causes significant bone or calcium problems.
- Ongoing blood tests tracking calcium, phosphate and hormone levels help clinicians fine-tune the treatment dose.
Managing calcium and bone health
The backbone of medical management is correcting the underlying calcium-vitamin D imbalance. Active vitamin D analogues such as alfacalcidol help restore normal calcium absorption and suppress PTH production, and are widely used in patients with secondary hyperparathyroidism linked to kidney disease. Alongside medication, regular monitoring of serum calcium, phosphate, and PTH levels guides dose adjustment. Bone health should be assessed periodically; the bone health category covers related medicines. For primary hyperparathyroidism with significantly elevated calcium or bone involvement, surgical removal of the affected gland remains the definitive option.
If you notice muscle weakness, persistent fatigue, frequent kidney stones, or unexplained bone pain, have your calcium and PTH checked promptly.